Daiichi Sankyo Reports 19.7% Revenue Growth in Q2 Driven by Oncology Portfolio
Daiichi Sankyo (DSKYF) reported strong second-quarter financial results, with global revenue rising 19.7% year-over-year to 1.167 trillion yen. This growth was primarily fueled by the robust performance of the company's global oncology medicines portfolio. Operating profit saw a significant increase of 34.4% compared to the previous year, reaching 193.8 billion yen. Despite these strong quarterly results, the company has opted to maintain its previously issued full fiscal year 2026 guidance, signaling confidence in its long-term strategic trajectory.
Topics: financial results oncology quarterly earnings
Read the full article at Seeking Alpha
Part of the story Japan Airlines Reports 12.2% Increase in Q2 Revenue and Reaffirms FY2027 Outlook (3 articles)